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Objectives: Antibiotic therapy of pulmonary Mycobacterium abscessus infection is based on a combination
treatment including clarithromycin. Recent data demonstrated that M. abscessus may carry a chromosomal,
inducible erm gene coding for the ribosomal methylase Erm(41). The purpose of this study was to investigate
whether in patients with chronic M. abscessus infection undergoing clarithromycin therapy, M. abscessus
acquires clarithromycin resistance mutations in the rrl gene in addition to the presence of an inducible
Erm(41) methylase.
Methods: We determined clarithromycin MICs, erm(41) and rrl sequences for 29 clinical M. abscessus subsp.
abscessus isolates of five different patients. The isolates were obtained between 2007 and 2011 covering a
longitudinal observation period of 2–4 years for the individual patients.
Results: In three out of five patients with an initial rrl wild-type isolate, follow-up isolates demonstrated acqui-
sition of resistance mutations in the rrl gene in addition to the presence of an inducible Erm methylase.
Conclusions: Our results show that in M. abscessus, clarithromycin resistance mutations in the 23S rRNA
peptidyltransferase region provide an additional selective advantage independent of a functional erm(41) gene.
Keywords: rapidly growing mycobacteria, drug susceptibility, cystic fibrosis, methylase
Introduction
Chronic pulmonary infections caused by rapidly growing myco-
bacteria (RGM) primarily affect hosts suffering from underlying
pulmonary diseases, e.g. bronchiectasis1 and cystic fibrosis
(CF).2–4 Approximately 80% of these infections are related
to Mycobacterium abscessus,5 which is considered to be the
most antibiotic-resistant species among all pathogenic RGM.6
M. abscessus infections are a major complication following lung
transplantation in CF patients.7
Antibiotic treatment of pulmonary M. abscessus infections
remains problematic, and surgical resection of focal bronchiec-
tasis and cavities is often required as part of the therapeutic
regimen.8,9 Recent studies concluded that although surgery
may prolong microbiological response, actual cure of the
disease can only be attained in a minority of cases.10,11 The
macrolide clarithromycin is considered a cornerstone in anti-
microbial chemotherapy of pulmonary M. abscessus infec-
tions.8,12,13 It is the only drug of demonstrated efficacy that
can be administered orally. Two main mechanisms of clarithro-
mycin resistance are well established. First, mutations in the
drug-binding pocket, in particular at nucleotide positions 2058
and 2059, of the bacterial 23S rRNA gene.14–17 Corresponding
mutations confer high-level resistance to clarithromycin
(MIC.256 mg/L) in bacterial species with a limited number of
chromosomal rRNA operons, including Mycobacterium chelonae
and M. abscessus.18–21 The second mechanism is conferred by
a class of genes coding for inducible erythromycin ribosomal
methylases (Erm), which mono- or di-methylate the adenine at
position 2058 of the 23S rRNA. Erm genes have been described
in many species of rapidly growing mycobacteria.22 Recently,
Nash et al.23 demonstrated that a representative of this gene
family, erm(41), is present in M. abscessus but not in the
closely related M. chelonae.
Erm genes in subspecies of M. abscessus show characteristic
differences. Compared with its homologues in M. abscessus
subsp. abscessus and M. abscessus subsp. bolletii, the Erm
methylase in M. abscessus subsp. massiliense is dysfunctional
due to a 2 bp deletion of nucleotides 64–65 and a 274 bp dele-
tion of nucleotides 159–432.23,24 In addition, the functionality of
the methylase is dependent on the nucleotide at position 28 of
the erm(41) gene. Wild-type T28 sequevars show inducible
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Table 1. Clarithromycin MICs and sequencing results of erm(41) and rrl genes
Patient Isolate Source
Date of isolation Clarithromycin MIC (mg/L) by method Genotype
month/year
months
since first
isolate
microdilution
Etest
erm(41)a
23S peptidyltransferase
region rpoBday 3 day 7 day 14 day 7
Control MAZ01.1 left forearm 08/08 0 0.5 1 1 0.064 C28 wild-type M. abscessus subsp.
abscessus
MAZ02 MAZ02.1 respiratory tract 06/08 0 1 .128 .128 0.5 T28 wild-type M. abscessus subsp.
abscessusMAZ02.2 respiratory tract 10/08 4 2 .128 .128 0.125 T28 wild-type
MAZ02.3 respiratory tract 02/09 8 2 .128 .128 0.25 T28 wild-type
MAZ02.4 respiratory tract 10/09 16 1 .128 .128 1 T28 wild-type
MAZ02.5 respiratory tract 08/11 38 0.5 128 .128 4–256 T28 wild-type
MAZ03 MAZ03.1 respiratory tract 01/09 0 0.5–8 64 128 0.25 T28 wild-type M. abscessus subsp.
abscessusMAZ03.2 respiratory tract 05/09 5 ,0.25 4 128 0.5 ND wild-type
MAZ03.3 respiratory tract 07/09 7 2 .128 .128 6–256 ND wild-type
MAZ03.4 respiratory tract 09/09 9 ,0.25 .128 .128 .256 T28 wild-type
MAZ03.5 respiratory tract 04/10 16 ,0.25 .128 .128 8–256 ND wild-type
MAZ03.6 respiratory tract 08/10 20 ,0.25 .128 .128 .256 ND wild-type
MAZ03.7 respiratory tract 12/10 23 ,0.25 .128 .128 .256 ND wild-type
MAZ03.8 respiratory tract 01/11 24 ,0.25 .128 .128 .256 T28 wild-type
MAZ03.9 wound secretion 01/11 24 ,0.25 .128 .128 .256 ND wild-type
MAZ04 MAZ04.1 sputum 04/07 0 ,0.25 8 64 0.032–0.5 T28 wild-type M. abscessus subsp.
abscessusMAZ04.2 sputum 07/08 15 0.5 .128 .128 0.25–256 T28 wild-type/2058AGb
MAZ04.3 sputum 08/09 28 32 .128 .128 .256 T28 2058AG
MAZ04.4 sputum 10/11 54 128 .128 .128 .256 T28 2058AG
MAZ07 MAZ07.1 respiratory tract 06/08 0 0.5 16 .128 0.19 T28 wild-type M. abscessus subsp.
abscessusMAZ07.2 respiratory tract 02/09 8 0.5 .128 .128 0.125–256 T28 wild-type/2058AGb
MAZ07.3 respiratory tract 04/09 10 1–128 .128 .128 1–256 T28 wild-type/2058AC/2058AGb
MAZ07.4 respiratory tract 09/09 15 2–128 .128 .128 1–256 T28 wild-type/2058AC/2058AGb
MAZ07.5 respiratory tract 12/09 18 .128 .128 .128 .256 T28 2058AC/2058AGb
MAZ07.6 respiratory tract 12/10 30 .128 .128 .128 .256 T28 2058AC/2058AGb
MAZ07.7 respiratory tract 01/11 31 .128 .128 .128 .256 T28 2058AC/2058AGb
MAZ08 MAZ08.1 respiratory tract 08/08 0 ,0.25 16 .128 1–256 T28 wild-type M. abscessus subsp.
abscessusMAZ08.2 respiratory tract 10/10 26 .128 .128 .128 .256 T28 wild-type/2058AGb
MAZ08.3 respiratory tract 12/10 28 .128 .128 .128 .256 T28 wild-type/2058AGb
MAZ08.4c respiratory tract 08/11 36 1 .128 .128 1.5–256 T28 wild-type
MC879d 850 sputum 06/91 0 0.5 4 32 ND T28 wild-type M. abscessus subsp.
abscessus852 sputum 09/93 27 .128 .128 .128 ND T28 2058AC
MC958d 855 BAL 11/91 0 0.5 16 .128 ND T28 wild-type M. abscessus subsp.
abscessus858 BAL 09/92 10 .128 .128 .128 ND T28 2059AG
MC1448d 868 sputum 08/94 0 .128 .128 .128 ND T28 2058AG M. abscessus subsp.
abscessus
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clarithromycin resistance, while C28 sequevars do not.23 Bastian
et al.24 recently reported that clinically acquired rrl mutations
conferring clarithromycin resistance were limited to M. abscessus
subsp. massiliense and M. abscessus subsp. abscessus C28
sequevars, both of which lack a functional Erm methylase,
while no such mutations were found in M. abscessus subsp.
abscessus T28 sequevars. This finding suggested that selection
for clarithromycin resistance mutations in the 23S rRNA gene is
less likely to occur in strains harbouring intact Erm methylases.24
In this study, we analysed a patient cohort suffering from
chronic M. abscessus infection for the development of constitu-
tive clarithromycin resistance during treatment. Patient isolates
were screened for the presence of the inducible erm(41) gene
and the occurrence of rrl mutations.
Materials and methods
Strains
In total, 29 clinical isolates of strains from five patients (MAZ02, MAZ03,
MAZ04, MAZ07 and MAZ08) were analysed in this study. As a control, the
clarithromycin-susceptible isolate MAZ01.1 was included. An additional
nine isolates of six clinical strains that had been described in a previous
study21 were subjected to re-evaluation. For all isolates, clarithromycin
MICs were determined, and rrl and erm(41) sequences were obtained.
Identification to subspecies level was performed by nucleic acid se-
quence analysis of the genes encoding 16S rRNA (rrs) and the b-
subunit of bacterial RNA polymerase (rpoB).25–27 In order to reflect the
biological properties of the strains with respect to clarithromycin resist-
ance, the terms M. abscessus subsp. abscessus, M. abscessus subsp.
bolletii and M. abscessus subsp. massiliense are used to refer to the re-
spective organisms throughout this paper.
Antibiotic susceptibility testing (AST)
Clarithromycin susceptibility testing was done in cation-adjusted
Mueller–Hinton medium using the broth microdilution method according
to CLSI guidelines.28 The clarithromycin breakpoints were ≤2 mg/L
(susceptible), 4 mg/L (intermediate) and ≥8 mg/L (resistant). Incubation
was continued for 14 days at 378C, with readings after 3, 5, 7, 9 and
14 days. Additionally, clarithromycin MICs were determined by the
Etest method (bioMe´rieux, Marcy l’E´toile, France).
PCR, nucleotide sequencing and strain typing
Total DNA was extracted from the bacterial isolates using InstaGene
matrix (Bio-Rad Laboratories, Hercules, CA, USA). The rrl gene was amp-
lified using primers SP1 (5′-CCTGCACGAATGGCGTAACG-3′) and SP2mod
(5′-CACCAGAGGTTCGTCCGTC-3′). Analysis of the erm(41) gene was per-
formed using primers erm41f2 (5′-TGGTATCCGCTCACTGATGA-3′; erm posi-
tions 34–53) and erm41r2 (5′-GCGGTGGATGATGGAAAG-3′; erm positions
484–467), which were designed using the published genome sequence
of M. abscessus strain ATCC 19977 (GenBank accession number
NC_010397.1) as the template. PCR conditions for both the rrl and
erm(41) amplifications were 5 min at 958C, followed by 40 cycles at
948C for 30 s, 558C for 30 s and 728C for 60 s. PCR amplicons were puri-
fied using Performa DTR cartridges (EdgeBio, Gaithersburg, MD, USA) and
sequenced with the corresponding forward and reverse primers on an
Applied Biosystems 3130 Genetic Analyser using BigDye Terminator
Cycle Sequencing chemistry (Applied Biosystems, Carlsbad, CA, USA).
For species identification, rrs and rpoB sequences were analysed using
Lasergene SeqMan software (DNASTAR, Madison, WI, USA) and compared
with reference sequences using the SmartGene database (SmartGene,Ta
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Zug, Switzerland) and the BLAST algorithm. To identify mutations in rrl,
sequences were compared with the published M. abscessus genome
(GenBank accession number NC_010397.1). Strains ATCC19977 (T28
sequevar, GenBank accession number FJ358483.1) and CR5701 (C28
sequevar, GenBank accession number HQ127366.1) were used as refer-
ence for erm(41) sequence analysis of all strains included in this study.
Strain typing was performed by randomly amplified polymorphic DNA
PCR (RAPD-PCR) as described previously.29 In brief, 100 ng of chromo-
somal DNA was used in four separate PCR reactions with 200 pmol of
random primers: INS-2, IS986-FP, OPA2 and OPA18. PCR amplification
used 40 cycles of 948C for 60 s, 368C for 60 s and 728C for 120 s. Ampli-
fication products were separated by electrophoresis on a 2% agarose gel
and detected using GelRed nucleic acid gel stain (Biotium Inc., Hayward,
CA, USA). Strain typing was performed for the first and last isolate of each
patient and for those isolates which showed a change in clarithromycin
susceptibility in comparison with an earlier isolate.
Results and discussion
A total of 29 clinical M. abscessus subsp. abscessus isolates
were obtained from five patients suffering from chronic infec-
tions. Isolates were recovered mainly from respiratory speci-
mens obtained over a period of 2–4 years, during which all
patients received antibiotic therapy including different clarithro-
mycin regimens. Clarithromycin MICs were determined by broth
microdilution and Etest assays. At the genetic level, isolates
were genotyped for the erm(41) polymorphism at position 28
and for resistance mutations in rrl (the 23S rRNA gene)
(Table 1). Strain typing was performed using RAPD-PCR and con-
sistent results were obtained for all four primers. On the basis
of these analyses, two different resistance patterns were
observed.
(i) M. abscessus isolates from patients MAZ02 and MAZ03
showed an inducible erm(41) gene and no rrl mutation ac-
quisition, during observation periods, 3 and 2 years, respect-
ively (Table 1). Both patients had been treated with various
antibiotic regimens containing clarithromycin, but exact
details (dosages, treatment intervals) were not available to
us. Isolates from patient MAZ03 produced identical
RAPD-PCR patterns (Figure 1), indicating that the same
strain had persisted. In contrast, strain typing of the
MAZ02 isolates showed different patterns, which can be
interpreted either as reinfection by a different strain or as a
mixed infection with a transition from one dominant
M. abscessus wild-type strain to another, with both strains
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Figure 1. Genotyping of M. abscessus isolates using RAPD-PCR. The isolates analysed were: (i) subsequent isolates of five patients MAZ02, MAZ03,
MAZ04, MAZ07 and MAZ08; and (ii) isolates published by Wallace et al.21 (isolates 850, 852, 855, 858, 859 and 860). Primers used in RAPD-PCRs
were: (a) INS-2, (b) IS986-FP, (c) OPA2 and (d) OPA18. MW, molecular weight standard.
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present since the beginning of the observation period
(Table 1 and Figure 1).
(ii) Initial isolates from patients MAZ04, MAZ07 and MAZ08 con-
tained an inducible erm(41) allele (T28 sequevars), but add-
itional rrl mutations resulting in constitutive clarithromycin
resistance were detected in subsequent isolates. Electropher-
ograms of the rrl genes of early follow-up isolates showed
A/C or A/G double peaks at position 2058 (Table 1), indicating
the emergence of a mutant population. At the phenotypic
level, growth at up to 256 mg/L clarithromycin on the
Etest plate was initially observed for single colonies only,
but appeared as dense bacterial lawns in later isolates,
reflecting the increasing dominance of the mutant (resist-
ant) population. Strain typing for isolates of patients
MAZ04 and MAZ07 revealed two different mechanisms
for rrl-mediated acquisition of high-level resistance in
M. abscessus subsp. abscessus populations with an intact
Erm methylase (Figure 1). A wild-type rrl population may
have been replaced by a mutant population of the same
strain (patient MAZ07), or a wild-type rrl strain may have
been replaced by a mutant population of a different strain
(patient MAZ04).
Acquisition and subsequent loss of a 2058AG mutation in
the rrl gene was observed in patient MAZ08. The first isolate,
MAZ08.1, showed a wild-type rrl. The second and third isolates,
MAZ08.2 and MAZ08.3, consisted of both wild-type and
mutated subpopulations. At this stage, administration of cla-
rithromycin was stopped, and treatment was continued with
amikacin, moxifloxacin and imipenem. Interestingly, the fourth
isolate (MAZ08.4), which was obtained 8 months after clarithro-
mycin was removed from the antibiotic regimen, showed a wild-
type rrl. Strain typing the different isolates was consistent with a
switch from one wild-type strain (MAZ08.1) to a different wild-
type strain (MAZ08.4) with intermediate mixed populations
containing both wild-type and mutant bacteria of different gen-
otypes (MAZ08.2 and MAZ08.3) (Figure 1).
These findings prompted us to reanalyse clarithromycin-
resistant M. abscessus isolates described in the 1996 study by
Wallace et al.,21 as at the time of the study M. abscessus had
been regarded as a single taxonomic entity (without subspecies
separation). The data further demonstrate that, regardless of a
functional or dysfunctional erm(41), high-level resistance to cla-
rithromycin emerging under drug therapy was associated with
mutations in 23S rRNA (Table 1).
The data presented in this study show that both erm- and
rrl-mediated resistance to clarithromycin can occur simultan-
eously in patient isolates, and that a functional Erm does not
exclude selection for rrl mutations as suggested previously.24
Erm methylases are known to produce different MIC values of
macrolides-lincosamides-streptogramin B (MLSB) and ketolide
antibiotics, depending on whether they act as mono- or dimethy-
lases on position 2058 of the 23S rRNA.30 Similar to other repre-
sentatives of this class of enzymes that have been described in
mycobacteria,22,31–33 Erm(41) is presumed to act as a mono-
methylase,23 although it might dimethylate a minor fraction of
ribosomal RNA. The occurrence of rrl mutations in strains with
intact erm(41) alleles may thus reflect a limited modification
of 23S rRNA position 2058 by monomethylation.
Our data maintain the paradigm that point mutations in 23S
rRNA constitute the main mechanism for acquired high-level re-
sistance in mycobacterial species which carry only a single rRNA
gene copy. The association of 23S rRNA mutations with clarithro-
mycin resistance in M. abscessus sensu lato indicates that,
despite an inducible erm(41), there is a selective advantage for
the acquisition of a 23S rRNA mutation, most probably due to
either increased mutation-associated antibiotic resistance or
less resistance-associated biological cost.17,34,35 It remains an
unresolved question as to whether patients carrying a wild-type
rrl strain with an inducible macrolide resistance determinant may
still benefit from clarithromycin treatment.
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